Antibody responses after intravaginal immunisation with trimeric HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation
about
Challenges in mucosal HIV vaccine development: lessons from non-human primate modelsMixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvantsUse of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoproteinTransferrin conjugation confers mucosal molecular targeting to a model HIV-1 trimeric gp140 vaccine antigen.Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140.Phase I randomised clinical trial of an HIV-1(CN54), clade C, trimeric envelope vaccine candidate delivered vaginallyEvaluation of TLR agonists as potential mucosal adjuvants for HIV gp140 and tetanus toxoid in mice.Comparison of neutralizing antibody responses elicited from highly diverse polyvalent heterotrimeric HIV-1 gp140 cocktail immunogens versus a monovalent counterpart in rhesus macaquesNewcastle disease virus expressing human immunodeficiency virus type 1 envelope glycoprotein induces strong mucosal and serum antibody responses in Guinea pigsInclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.Characterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope.Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre Study.Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial.New prospects for a preventive HIV-1 vaccine.Biology of mucosally transmitted sexual infection-translating the basic science into novel HIV intervention: a workshop summary.Mucosal vaccine adjuvants update.Mucosal vaccines: novel strategies and applications for the control of pathogens and tumors at mucosal sites.Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates.Microneedle mediated intradermal delivery of adjuvanted recombinant HIV-1 CN54gp140 effectively primes mucosal boost inoculations.Modulation of HIV-1 immunity by adjuvants.Unique cellular and humoral immunogenicity profiles generated by aerosol, intranasal, or parenteral vaccination in rhesus macaques.Nanoparticle orientationally displayed antigen epitopes improve neutralizing antibody level in a model of porcine circovirus type 2.Determination of molecular size parameters and quantification of polyacrylic acid by high performance size-exclusion chromatography with triple detection.
P2860
Q27022152-579C09D1-143F-43D4-98D4-13C1D288F700Q27304735-32D6BECC-130C-41C4-B773-D6EDCB66E223Q28730561-D84B4D5C-78F9-433C-B5E2-C5A0B4777AC3Q30468622-4CBD332F-DEA7-4D0D-A956-D4C9D6AB2B87Q31076192-6EF4CC6E-B8FB-47E1-97A6-888CCFF17F3AQ34044915-83B0166A-11F4-435D-BA1E-EDEC75528294Q34524955-0A629FC5-184C-432E-9AAD-1DF3D5FC8BEFQ34663118-9305B7B8-E19A-409E-8F9A-9AB9C5E992DEQ35275117-F0205066-7D77-40D1-8066-35482873AD11Q35883032-277C2DB4-E4AF-4B49-A93F-D74189B9EDE9Q35914362-97702D64-1A6C-45C5-8410-1C54E4378AA3Q36012177-96014B0D-D873-4994-A76F-8A47EEAF2940Q36021144-E1BF3B76-1B67-42FD-AE93-991C48A26841Q36223864-47466DEA-A3D4-46C5-ADA5-BEABD821BF7EQ36358993-94C435C7-8332-4E26-99C8-727239E893AFQ36758075-DC2707AC-3146-40DE-B6A8-C82B9AD80A54Q36978334-55CFC0D7-CFD9-4E9A-BAEA-A5AD9344AE33Q37069793-F0B8FF4B-44F8-4ADE-B66A-20A2466ED655Q37187433-C308663C-DB9B-46B5-B00C-A3FCDCDA9833Q37698564-07E96965-F4DB-47A4-A230-3BB2F7AD636BQ39045080-F9BB5C50-80DD-4E32-B105-730DE68F6972Q40109161-BD49B0C5-35C3-4CCB-8E3E-25BF0A7B5AEEQ47244041-0D44250C-4FB8-4913-9A9E-2093875A6CCF
P2860
Antibody responses after intravaginal immunisation with trimeric HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Antibody responses after intra ...... with an adjuvanted formulation
@ast
Antibody responses after intra ...... with an adjuvanted formulation
@en
Antibody responses after intra ...... with an adjuvanted formulation
@nl
type
label
Antibody responses after intra ...... with an adjuvanted formulation
@ast
Antibody responses after intra ...... with an adjuvanted formulation
@en
Antibody responses after intra ...... with an adjuvanted formulation
@nl
prefLabel
Antibody responses after intra ...... with an adjuvanted formulation
@ast
Antibody responses after intra ...... with an adjuvanted formulation
@en
Antibody responses after intra ...... with an adjuvanted formulation
@nl
P2093
P2860
P50
P1433
P1476
Antibody responses after intra ...... with an adjuvanted formulation
@en
P2093
A Nasir Mahmoud
Alethea Cope
Carol A Fraser
Elaine Giles
Gerald Voss
Joanna Hall
Martin P Cranage
Michael S Seaman
P2860
P304
P356
10.1016/J.VACCINE.2010.12.034
P407
P577
2010-12-25T00:00:00Z